Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERA: 1 vs 2 years of adjuvant Herceptin
NCT00045032Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2001
- Primary completion
- Mar 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 33
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by Roche. Started Nov 2001; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00045032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045032.